Main Article Content
Type 2 diabetes mellitus is a disease of impaired glucose homeostasis and chronic hyperglycemia. Current approaches for the treatment frequently involving the use of combination therapy. The aim of the present study was to evaluate and compare the hypoglycaemic activity of fixed-dose combination anti-diabetic formulations and respective individual agents using rabbits as an animal model. Experimental diabetes was induced by a single intravenous injection of alloxan monohydrate at a dose of 150 mg/kg. Individual drugs and combination tablets were administered to experimental groups. Fasting blood glucose level was estimated at 0, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours using glucometer. Data were statistically analyzed using student t-test and p less than 0.05 considered as statistically significant. The reduction in fasting blood glucose level in diabetes-induced rabbits was significantly higher with combination products compared to individual drugs. Fixed-dose combination products had shown improved glycaemic control than individual agents. Fixed-dose combination therapy can be used as a suitable option for selected patients requiring multiple glucose-lowering therapies for use as an adjunct to diet and exercise to improve glycaemic control in type 2 diabetes mellitus.
Download data is not yet available.
How to Cite
Chinta R, Pilli R. Comparative Hypoglycaemic Activity of Fixed Dose Combination Anti-Diabetic Formulations Versus Respective Monotherapies in Diabetic Rabbits. ijpqa [Internet]. 2020 Sep. 25 [cited 2021 Aug. 1];11(03):409-16. Available from: http://ijpqa.openresearchjournals.com/index.php/ijpqa/article/view/504